Staff Directory Contact Us

The Nathan S. Kline Institute for Psychiatric Research

Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Length: 
One week
Disorder/Condition: 
Schizophrenia
Inclusion Criteria: 
  • Inpatients with DSM-5 diagnosis of schizophrenia
  • English-speaking
  • WRAT-4 reading ≥ 8th grade level
  • 18-60 years of age
  • Have negative symptoms: which includes diminished vocal expression, decreased or increased vocal production, and difference in intonations when speaking                                                                                                                                                                                                                                                                                                                                                                                          
Study Title (brief): 
Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia
Study Description (brief): 

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Contact: 

For more information about this study, please contact Shuaib Ahmad, research coordinator, at 646-766-5869 or Shuaib.Ahmad@omh.ny.gov.

Exclusion Criteria: 
  • Have another DSM-5 diagnosis such as schizoaffective disorder, bipolar disorder, major depressive disorder, or tardive dyskinesia that is moderate to severe or requires treatment
  • Significant medical and/or major neurologic disorder
  • Clinically relevant abnormal movement disorders
Study Location: 
Manhattan Psychiatric Center, Ward's Island Complex, NY